Glaxosmithkline Plc Adr Stock Filter Stocks by Fundamentals
| GSK Stock | USD 33.70 0.35 1.05% |
GlaxoSmithKline PLC ADR fundamentals help investors to digest information that contributes to GlaxoSmithKline PLC's financial success or failures. It also enables traders to predict the movement of GlaxoSmithKline Stock. The fundamental analysis module provides a way to measure GlaxoSmithKline PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlaxoSmithKline PLC stock.
GlaxoSmithKline | Shares Owned by Insiders |
GlaxoSmithKline PLC Current Valuation Drivers
We derive many important indicators used in calculating different scores of GlaxoSmithKline PLC from analyzing GlaxoSmithKline PLC's financial statements. These drivers represent accounts that assess GlaxoSmithKline PLC's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of GlaxoSmithKline PLC's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 70.1B | 53.6B | 52.2B | 58.5B | 119.8B | 125.8B | |
| Enterprise Value | 95.9B | 74.5B | 72.1B | 75.7B | 134.9B | 141.6B |
GlaxoSmithKline PLC ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, GlaxoSmithKline PLC's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to GlaxoSmithKline PLC's managers, analysts, and investors.Environmental | Governance | Social |
GlaxoSmithKline PLC Institutional Holders
Institutional Holdings refers to the ownership stake in GlaxoSmithKline PLC that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of GlaxoSmithKline PLC's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing GlaxoSmithKline PLC's value.| Shares | Goldman Sachs Group Inc | 2024-06-30 | 4.2 M | Eversept Partners, Llc | 2024-09-30 | 4.1 M | Provident Trust Company | 2024-09-30 | 4 M | Grantham, Mayo, Van Otterloo & Co., Llc | 2024-09-30 | 3.7 M | Hsbc Holdings Plc | 2024-06-30 | 3.6 M | Equity Investment Corp | 2024-09-30 | 3.5 M | Lmr Partners Llp | 2024-06-30 | 3.3 M | Camber Capital Management Llc | 2024-09-30 | 3 M | Hotchkis & Wiley Capital Management Llc | 2024-06-30 | 2.7 M | Dodge & Cox | 2024-09-30 | 68.1 M | Fmr Inc | 2024-09-30 | 29 M |
GlaxoSmithKline Fundamentals
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.0724 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 83.64 B | ||||
| Shares Outstanding | 2.04 B | ||||
| Shares Owned By Insiders | 0.06 % | ||||
| Shares Owned By Institutions | 15.38 % | ||||
| Number Of Shares Shorted | 16.29 M | ||||
| Price To Earning | 11.80 X | ||||
| Price To Book | 3.83 X | ||||
| Price To Sales | 2.17 X | ||||
| Revenue | 30.33 B | ||||
| Gross Profit | 19.92 B | ||||
| EBITDA | 9.08 B | ||||
| Net Income | 4.93 B | ||||
| Cash And Equivalents | 3.72 B | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 18.02 B | ||||
| Debt To Equity | 0.98 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 3.43 X | ||||
| Cash Flow From Operations | 6.77 B | ||||
| Short Ratio | 3.29 X | ||||
| Earnings Per Share | 1.54 X | ||||
| Price To Earnings To Growth | 0.71 X | ||||
| Target Price | 45.95 | ||||
| Number Of Employees | 70.21 K | ||||
| Beta | 0.33 | ||||
| Market Capitalization | 68.04 B | ||||
| Total Asset | 59.01 B | ||||
| Retained Earnings | 7.74 B | ||||
| Working Capital | (2.42 B) | ||||
| Current Asset | 16.59 B | ||||
| Current Liabilities | 13.42 B | ||||
| Annual Yield | 0.05 % | ||||
| Five Year Return | 5.32 % | ||||
| Net Asset | 59.01 B | ||||
| Last Dividend Paid | 0.61 |
About GlaxoSmithKline PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out GlaxoSmithKline PLC Piotroski F Score and GlaxoSmithKline PLC Altman Z Score analysis. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.28) | Dividend Share 0.61 | Earnings Share 1.54 | Revenue Per Share 15.38 | Quarterly Revenue Growth (0.02) |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.